JERUSALEM, June 23, 2014 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)
(http://www.oramed.com), a clinical-stage pharmaceutical company
focused on the development of oral drug delivery systems, announced
today that its Chief Executive Officer, Nadav Kidron, will present at the 2014 BIO
International Convention. This year's global event for
biotechnology will take place on June
23-26 at the San Diego
Convention Center in San Diego,
California.
Presentation Details:
2014 BIO International Convention
Date: Thursday, June 26, 2014
Time: 10:30am Pacific Time
Location: San Diego Convention
Center, Pacific Beach room
About the BIO International Convention
The BIO International Convention, the largest global event for
the biotechnology industry, will highlight the latest trends and
the newest opportunities for executives, investors, scientists,
policy leaders, and media from around the world. Speakers at the
sessions will share breakthroughs in medicine, diagnostics, the
environment, energy production, business operations, financing,
partnerships, policy issues and food and agriculture. The
Convention also features the BIO Business Forum, a unique platform
for biotechnology and pharmaceutical companies, academic research
institutions, and investors from around the world to gather and
discuss strategic opportunities. For more information about the BIO
International Convention please visit convention.bio.org.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs currently delivered via
injection. Established in 2006, Oramed's Protein Oral Delivery
(POD[TM]) technology is based on
over 30 years of research by top research scientists at
Jerusalem's Hadassah Medical
Center. Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally
ingestible insulin capsule (ORMD-0801) currently in separate Phase
II clinical trials in patients with both type 1 and type 2 diabetes
under an Investigational New Drug (IND) application with the U.S.
FDA, and with its oral GLP-1 analog capsule (ORMD-0901) entering
IND-enabling studies later this year.
For more information, the content of which is not part of
this press release, please
visit http://www.oramed.com
Forward-looking statements: This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, we are using
forward-looking statements when we discuss our clinical trials,
including the timing thereof, the effects of ORMD-0801 and oral
insulin in general, and revolutionizing the treatment of diabetes
with our products. These forward-looking statements are based on
the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and Exchange
Commission.
Company Contact:
Oramed Pharmaceuticals
Aviva Guiloff
Office: +972-2-566-0001 ext. 2
US: 1-718-831-2512 ext. 2
Email: aviva@oramed.com
SOURCE Oramed Pharmaceuticals Inc.